Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis

References

• Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 2015;115:24--31
   PubMed Web of Science ®Google Scholar
• Gacci M, Sebastianelli A, Salvi M, et al. Central obesity is predictive of persistent storage LUTS after surgery for benign prostatic enlargement: results of a multicenter prospective study. BJU Int 2015 Jan 18. doi: 10.1111/bju.13038
   Web of Science ®Google Scholar
• Lee RK, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012;110:540–5
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Privitera S, et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int 2015 Jan 20. doi: 10.1111/bju.13053
   Web of Science ®Google Scholar
• Vanella L, Russo GI, Cimino S, et al. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia. Urology 2014;83:1444 e7–13
   PubMed Web of Science ®Google Scholar
• Lee YC, Liu CC, Huang CN, et al. The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males. J Sex Med 2010;7:3127–34
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. J Sex Med 2014;11:1159–72
   PubMed Web of Science ®Google Scholar
• Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101–16
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013;73:1391–402
   PubMed Web of Science ®Google Scholar
• Sebastiano C, Vincenzo F, Tommaso C, et al. Dietary patterns and prostatic diseases. Front Biosci (Elite Ed) 2012;4:195–204
   PubMedGoogle Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29–34
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013;32:230–7
   PubMed Web of Science ®Google Scholar
• Tsai CC, Liu CC, Huang SP, et al. The impact of irritative lower urinary tract symptoms on erectile dysfunction in aging Taiwanese males. Aging Male 2010;13:179–83
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine 2009;6:e1000100
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 26 June 2015
   Google Scholar
• De Nunzio C, Cindolo L, Gacci M, et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 2014;84:1181–7
   PubMed Web of Science ®Google Scholar
• Jeong JH, Kim ET, Kim DK. Association of metabolic syndrome and benign prostate enlargement in young korean males. Korean J Urol 2011;52:757–62
   PubMedGoogle Scholar
• Kim JH, Doo SW, Yun JH, Yang WJ. Lower likelihood of having moderate-to-severe lower urinary tract symptoms in middle-aged healthy Korean men with metabolic syndrome. Urology 2014;84:665–9
   PubMed Web of Science ®Google Scholar
• Ohgaki K, Hikima N, Horiuchi K, Kondo Y. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score. Urology 2011;77:1432–8
   PubMed Web of Science ®Google Scholar
• Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urol 2007;51:199–203; discussion 4–6
   PubMed Web of Science ®Google Scholar
• Park HK, Lee HW, Lee KS, et al. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008;72:556–60
   PubMed Web of Science ®Google Scholar
• Park YW, Kim SB, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674–9
   PubMed Web of Science ®Google Scholar
• Russo GI, Cimino S, Fragala E, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. J Sex Med 2014;11:2074–82
   PubMed Web of Science ®Google Scholar
• Wang CC, Chancellor MB, Lin JM, et al. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int 2010;105:1136–40
   PubMed Web of Science ®Google Scholar
• Yang TK, Hsieh JT, Chen SC, et al. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012;80:1093–7
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng X, Liu Y, et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93:214–19
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. European Urol 2012;61:560–70
   PubMed Web of Science ®Google Scholar
• Byun HK, Sung YH, Kim W, et al. Relationships between prostate-specific antigen, prostate volume, and components of metabolic syndrome in healthy Korean men. Korean J Urol 2012;53:774–8
   PubMedGoogle Scholar
• Yim SJ, Cho YS, Joo KJ. Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age. Korean J Urol 2011;52:390–5
   PubMedGoogle Scholar
• Gao Y, Wang M, Zhang H, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology 2012;79:194–201
   PubMed Web of Science ®Google Scholar
• Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009;182:616–24; discussion 24–5
   PubMed Web of Science ®Google Scholar
• Pashootan P, Ploussard G, Cocaul A, et al. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int 2014 Sep 17. doi: 10.1111/bju.12931
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29:310–16
   PubMed Web of Science ®Google Scholar
• Minutoli L, Altavilla D, Marini H, et al. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene. J Biomed Sci 2014;21:19
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. European Urol 2014;66:619–22
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Cellai I, Santi R, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012;214:31–43
   PubMed Web of Science ®Google Scholar
• Lee S, Min HG, Choi SH, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006;14:172–9
   PubMed Web of Science ®Google Scholar
• Muller RL, Gerber L, Moreira DM, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. European Urol 2013;63:1115–21
   PubMed Web of Science ®Google Scholar
• Russo GI, Cimino S, Fragala E, et al. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol 2015;33:743--51
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, O'Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 2013;16:169–72
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53–8
   PubMed Web of Science ®Google Scholar
• Yassin DJ, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 2014;32:1049–54
   PubMed Web of Science ®Google Scholar
• Favilla V, Cimino S, Castelli T, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int 2010;106:1700–3
   PubMed Web of Science ®Google Scholar
• Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359–64
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010;13:242–6
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–76
   PubMed Web of Science ®Google Scholar
• Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57–61
   PubMed Web of Science ®Google Scholar
• Karazindiyanoglu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146–9
   PubMed Web of Science ®Google Scholar
• Chavalmane AK, Comeglio P, Morelli A, et al. Sex steroid receptors in male human bladder: expression and biological function. J Sex Med 2010;7:2698–713
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men Aging Male 2015;18:5–15
   PubMed Web of Science ®Google Scholar
• Kirby MG, Wagg A, Cardozo L, et al. Overactive bladder: is there a link to the metabolic syndrome in men? Neurourol Urodyn 2010;29:1360–4
   PubMed Web of Science ®Google Scholar